文献速递头颈与中枢神经肿瘤

同步放化疗后辅助顺铂-吉西他滨对比顺铂-氟尿嘧啶治疗N2-3期鼻咽癌:多中心、开放标签、随机对照3期试验

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2023-06-05

这项在中国四家癌症中心开展的开放标签随机3期试验纳入240例N2-3期鼻咽癌患者,比较同步放化疗后辅助顺铂-吉西他滨与顺铂-氟尿嘧啶的疗效与安全性。顺铂-吉西他滨组3年无进展生存率为83.9%,顺铂-氟尿嘧啶组为71.5%(分层HR 0.54,95%CI 0.32-0.93;log rank p=0.023)。作者认为顺铂-吉西他滨可作为N2-3期鼻咽癌的辅助治疗,但需长期随访确认最佳治疗比。

要点

  • 顺铂-吉西他滨组3年无进展生存率83.9%,顺铂-氟尿嘧啶组71.5%,分层HR 0.54(95%CI 0.32-0.93)。
  • 3级及以上白细胞减少顺铂-吉西他滨组52% vs 顺铂-氟尿嘧啶组29%(p=0.00039)。
  • 顺铂-吉西他滨组1例治疗相关死亡(中性粒细胞减少性感染所致感染性休克)。

核心结论

  • 作者认为同步辅助顺铂-吉西他滨可作为N2-3期鼻咽癌的辅助治疗,但需长期随访确认最佳治疗比。

研究设计与样本

  • 开放标签、随机对照、3期试验,在中国四家癌症中心开展。
  • 2017年10月30日至2020年7月9日随机分配240例患者(中位年龄44岁[IQR 36-52];男175例[73%],女65例[27%]),顺铂-氟尿嘧啶组120例、顺铂-吉西他滨组120例。
  • 入组标准为18-65岁、未经治疗的非角化型T1-4 N2-3 M0鼻咽癌、ECOG体能状态评分0-1、骨髓肝肾功能充足。
  • 随机按1:1计算机生成随机数、区组大小6,按治疗中心和淋巴结分期分层。
  • 主要终点为意向治疗人群的3年无进展生存率;安全性在所有至少接受一剂放化疗的参与者中评估。

主要发现

  • 截至2022年12月25日数据截止,中位随访40个月(IQR 32-48)。
  • 3年无进展生存率顺铂-吉西他滨组83.9%(95%CI 75.9-89.4;疾病进展19例、死亡11例) vs 顺铂-氟尿嘧啶组71.5%(95%CI 62.5-78.7;疾病进展34例、死亡7例),分层风险比0.54(95%CI 0.32-0.93),log rank p=0.023。
  • 治疗期间最常见的3级及以上不良事件:白细胞减少顺铂-吉西他滨组61/117例(52%) vs 顺铂-氟尿嘧啶组34/116例(29%),p=0.00039;中性粒细胞减少37例(32%) vs 19例(16%),p=0.010;黏膜炎27例(23%) vs 32例(28%),p=0.43。
  • 放疗完成后3个月起最常见的3级及以上晚期不良事件为听觉或听力丧失,顺铂-吉西他滨组6例(5%) vs 顺铂-氟尿嘧啶组10例(9%)。
  • 顺铂-吉西他滨组1例(1%)患者死于治疗相关并发症(中性粒细胞减少性感染所致感染性休克);顺铂-氟尿嘧啶组无治疗相关死亡。

临床怎么用

  • 作者认为同步辅助顺铂-吉西他滨可用于N2-3期鼻咽癌的辅助治疗,但需长期随访确认最佳治疗比。

局限性

  • 作者指出需要长期随访以确认最佳治疗比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with N2-3 nasopharyngeal carcinoma have a high risk of treatment being unsuccessful despite the current practice of using a concurrent adjuvant cisplatin-fluorouracil regimen. We aimed to compare the efficacy and safety of concurrent adjuvant cisplatin-gemcitabine with cisplatin-fluorouracil in N2-3 nasopharyngeal carcinoma. METHODS: We conducted an open-label, randomised, controlled, phase 3 trial at four cancer centres in China. Eligible patients were aged 18-65 years with untreated, non-keratinising, stage T1-4 N2-3 M0 nasopharyngeal carcinoma, an Eastern Cooperative Oncology Group performance status score of 0-1, and adequate bone marrow, liver, and renal function. Eligible patients were randomly assigned (1:1) to receive concurrent cisplatin (100 mg/m2 intravenously) on days 1, 22, and 43 of intensity-modulated radiotherapy followed by either gemcitabine (1 g/m2 intravenously on days 1 and 8) and cisplatin (80 mg/m2 intravenously for 4 h on day 1) once every 3 weeks or fluorouracil (4 g/m2 in continuous intravenous infusion for 96 h) and cisplatin (80 mg/m2 intravenously for 4 h on day 1) once every 4 weeks, for three cycles. Randomisation was done using a computer-generated random number code with a block size of six, stratified by treatment centre and nodal category. The primary endpoint was 3-year progression-free survival in the intention-to-treat population (ie, all patients randomly assigned to treatment). Safety was assessed in all participants who received at least one dose of chemoradiotherapy. This study was registered at ClinicalTrials.gov, NCT03321539, and patients are currently under follow-up. FINDINGS: From Oct 30, 2017, to July 9, 2020, 240 patients (median age 44 years [IQR 36-52]; 175 [73%] male and 65 [27%] female) were randomly assigned to the cisplatin-fluorouracil group (n=120) or cisplatin-gemcitabine group (n=120). As of data cutoff (Dec 25, 2022), median follow-up was 40 months (IQR 32-48). 3-year progression-free survival was 83·9% (95% CI 75·9-89·4; 19 disease progressions and 11 deaths) in the cisplatin-gemcitabine group and 71·5% (62·5-78·7; 34 disease progressions and seven deaths) in the cisplatin-fluorouracil group (stratified hazard ratio 0·54 [95% CI 0·32-0·93]; log rank p=0·023). The most common grade 3 or worse adverse events that occurred during treatment were leukopenia (61 [52%] of 117 in the cisplatin-gemcitabine group vs 34 [29%] of 116 in the cisplatin-fluorouracil group; p=0·00039), neutropenia (37 [32%] vs 19 [16%]; p=0·010), and mucositis (27 [23%] vs 32 [28%]; p=0·43). The most common grade 3 or worse late adverse event (occurring from 3 months after completion of radiotherapy) was auditory or hearing loss (six [5%] vs ten [9%]). One (1%) patient in the cisplatin-gemcitabine group died due to treatment-related complications (septic shock caused by neutropenic infection). No patients in the cisplatin-fluorouracil group had treatment-related deaths. INTERPRETATION: Our findings suggest that concurrent adjuvant cisplatin-gemcitabine could be used as an adjuvant therapy in the treatment of patients with N2-3 nasopharyngeal carcinoma, although long-term follow-up is required to confirm the optimal therapeutic ratio. FUNDING: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Major Project of Basic and Applied Basic Research, Sci-Tech Project Foundation of Guangzhou City, Sun Yat-sen University Clinical Research 5010 Program, Innovative Research Team of High-level Local Universities in Shanghai, Natural Science Foundation of Guangdong Province for Distinguished Young Scholar, Natural Science Foundation of Guangdong Province, Postdoctoral Innovative Talent Support Program, Pearl River S&T Nova Program of Guangzhou, Planned Science and Technology Project of Guangdong Province, Key Youth Teacher Cultivating Program of Sun Yat-sen University, the Rural Science and Technology Commissioner Program of Guangdong Province, and Fundamental Research Funds for the Central Universities.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Liu LT, Liu H, Huang Y, et al. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2023. PMID: 37290468. doi:10.1016/S1470-2045(23)00232-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。